New outlook for neuroendocrine cancer. Two agents dramatically delayed the time to disease progression in metastatic neuroendocrine tumors, according to reports at the 2009 Gastrointestinal Cancers Symposium. The PROMID study (Placebo-controlled prospective Randomized study on the antiproliferative efficacy of Octreotide LAR in patients with metastatic neuroendocrine MIDgut tumors) evaluated the antitumor effects of the somatostatin analog octreotide acetate (Sandostatin LAR), which already is used to treat the severe diarrhea and flushing associated with neuroendocrine tumors (NET). Read More →

File Type: pdf
Categories: Neuroendocrine, Octreotide